Pharmacokinetics and Pharmacodynamics of Clozapine

Clinical Pharmacokinetics

Volumn 24, Issue 2, 1993, Pages 161-176

  Jann, Michael W ^a,b   Griley, Sara R ^a,b   Gray, Eric C ^a,b   Chang, Wen Ho ^a,b  

^a MERCER UNIVERSITY   (United States)

^b TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR; DRUG METABOLITE; HALOPERIDOL; HOMOVANILLIC ACID; PROLACTIN;

AGRANULOCYTOSIS; CHINESE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JEW; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PHARMACOGENETICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RACE DIFFERENCE; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEIZURE; SEIZURE THRESHOLD; TARDIVE DYSKINESIA; URINARY EXCRETION;

CLOZAPINE; HUMAN; SCHIZOPHRENIA;

EID: 0027469978     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199324020-00005     Document Type: Review

References (94)

1. Clozapine: pharmacokinetic investigations and biochemical effects
2. Antipsychotic efficacy in relation to plasma concentrations of clozapine
3. Report on schizophrenia of the American College of Neuropsychopharmacology
4. GMCSF treatment of clozapine induced agranulocytosis: a case
5. The pharmacology and biochemistry of N-oxides
6. Clozapine for the treatment of adolescents with schizophrenia
7. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin receptors
8. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection
9. Relationship between effects and plasma concentrations of clozapine
10. Measurement of plasma concentrations of tricyclic psychoactive drugs and their metabolites by UV reflectance photometry of thin layer chromatography
11. Binding of typical and atypical antipsychotics to 5-HT-1C and 5-HT-2 sites: clozapine potently interacts with 5-HT-1C sites
12. Clozapine: neuroleptic induced EPS and tardive dyskinesia
13. Time-response curves of homovanillic acid in caudate and prefrontal cortex following acute neuroleptic administration
14. Clinical pharmacokinetics of clozapine in schizophrenic patients
15. Single vs multiple dose pharmacokinetics of clozapine in psychiatric patients
16. Multiple dose pharmacokinetics of clozapine in patients
17. Drug-induced agranulocytosis: review of possible mechanisms and prospects for clozapine studies
18. Review: D-1 dopamine receptor — the search for a function
19. Seizure activity associated with antipsychotic therapy
20. Molecular dynamics of dopamine at the D-2 receptor
21. Molecular cloning and expression of the gene for a human D-1 dopamine receptor
22. Clozapine-related seizures
23. Positron emission tomography analysis of central D-1 and D-2 dopamine receptor occupancy in patients with classical neuroleptics and clozapine
24. The antipsychotic clozapine is metabolised by the polymorphic human microsomal and recombinant cytochrome P450 2D6
25. Central D-2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
26. D-1 and D-2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
27. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia
28. The metabolism of 8-chloro-11-(4-methyll-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine) in mice, dogs and human subjects
29. Alternative splicing directs the expression of two D-2 dopamine receptor isoforms
30. Serotonin receptors: clinical implications
31. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia
32. Plasma HVA and response to clozapine
33. Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AUMP program
34. Pharmacokinetic study of clozapine
35. Clozapine and seizures
36. Dose-related plasma concentrations of clozapine
37. Influence of patient related variables on clozapine plasma concentrations
38. Clozapine plasma concentrations determined by high performance liquid chromatography with ultraviolet detection
39. Dose-related plasma concentrations of clozapine: influence of smoking behavior, sex, and age
40. Influence of clozapine on EEG
41. Serum concentrations of clozapine determined by nitrogen selective gas chromatography
42. The history of clozapine
43. Therapeutic monitoring of chlorpromazine: I. Pitfalls in plasma analysis
44. First analysis of a prospective clozapine drug monitoring study
45. Rapid and sensitive determination of clozapine in human plasma using high-performance liquid chromatography and amperometric detection
46. Clozapine
47. Tolerability and therapeutic effect of clozapine
48. Clozapine: plasma concentrations and prolactin response
49. Clozapine for the treatment-resistant schizophrenic
50. Plasma concentration vs clinical and biochemical effects of thioridazine, clozapine, benperidol, penfluridol in acutely schizophrenic patients
51. Leponex-associated granulocytosis: review of the situation
52. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency
53. Therapeutic effects of clozapine
54. Clozapine overdosage
55. N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function
56. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs
57. Clozapine in tardive dyskinesia
58. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia
59. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years
60. The assay of clozapine and N-desmethylclozapine in human plasma by high performance liquid chromatography
61. Who should receive clozapine?
62. Expression of the dopamine D-2 receptor gene in brain
63. The mechanism of action of novel antipsychotic drugs
64. Effect of clozapine on human serum prolactin concentrations
65. Bioanalytical assay of clozapine and its N-oxide metabolite and the determination of their blood concentrations in the dog
66. Effect of Phenytoin on plasma clozapine concentration in two patients
67. Clozapine overdosage
68. Severe intoxication with Leponex® and its intensive treatment
69. A survey of clozapine treatment
70. Clozapine and nor-clozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients
71. Clinical and biologic response to clozapine in patients with schizophrenia
72. Clozapine in China: a review and preview of US/PRC collaboration
73. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects
74. Determination of clozapine in human serum by capillary gas chromatography
75. Non-equilibrium method for the radioimmunoassay of clozapine in the presence of metabolites
76. Update on the clinical efficacy and side effects of clozapine
77. Some reflections on molecular structure and biological activity of tricyclic neuroleptics
78. Reversal by physostigmine of clozapine-induced delirium
79. PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness
80. Premarketing observational studies of population pharmacokinetics of new drugs
81. Clozapine plasma concentrations and convulsions
82. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant psychosis
83. Molecular cloning and characterization of a novel dopamine receptor D-3 as a target for neuroleptics
84. Cloning of the gene for a human dopamine D-5 receptor with a higher affinity for dopamine than D-1
85. A case report of Cimetidine induced clozapine toxicity
86. Clozapine treatment of schizophrenic patients
87. EEG abnormalities associated with clozapine treatment
88. Cloning of the gene for a human dopamine D-4 receptor with high affinity for the antipsychotic clozapine
89. Antagonism by neuroleptics of serotonin 5-HT-1A and 5-HT-2 receptors of normal human brain in vitro
90. Central D-1 and D-2 receptor occupancy during antipsychotic treatment
91. High-performance liquid chromatography procedure for the determination of clozapine, haloperidol, droperidol, and several benzodiazepines in plasma
92. Biochemistry and schizophrenia (part IV): the neuroleptics — their mechanism of action: a review of the biochemical literature
93. Determination of clozapine and its metabolites in serum and urine by reverse phase HPLC
94. Cloning and expression of human and rat D-1 dopamine receptors